Perceptive allies with Garabedian on $210M early-stage fund by Nick Paul Taylor Tuesday, December 10, 2019 The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.
Sarepta pays StrideBio $48M for preclinical gene therapies by Nick Paul Taylor Friday, November 15, 2019 The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.
Pfizer's DMD gene therapy safety data hand advantage to Sarepta by Nick Paul Taylor Monday, July 1, 2019 One of the first six people to receive the treatment was hospitalized with acute renal injury, leading analysts to talk down Pfizer’s chances.
Sarepta pulls the trigger on $165M Myonexus buy by Amirah Al Idrus Wednesday, February 27, 2019 Sarepta licensed five gene therapies for limb-girdle muscular dystrophy from Myonexus last May. Now it's buying Myonexus outright for $165 million.
CRISPR corrects DMD in mice for a year in Sarepta-supported study by Arlene Weintraub Monday, February 18, 2019 A Duke lab at the center of a research pact with Sarepta is reporting promising results from a trial of CRISPR gene editing in mouse models of DMD.
Solid Bio plummets on early DMD gene therapy readout by Phil Taylor Thursday, February 7, 2019 Solid Bio’s run of negative news is continuing with another setback for its Duchenne muscular dystrophy gene therapy.
After gene therapy pivot, Axovant bolsters its executive ranks by Amirah Al Idrus Monday, November 26, 2018 After refocusing on gene therapy, Axovant is appointing five new executives to posts ranging from clinical development to commercial operations.
Sarepta sees muscle gains with DMD gene therapy by Phil Taylor Thursday, October 4, 2018 Preliminary signs of improved muscle function have been seen in Sarepta's Duchenne muscular dystrophy gene therapy trial.
Quality blip halts Sarepta DMD gene therapy trial by Phil Taylor Thursday, July 26, 2018 A trial of Sarepta’s gene therapy for muscular dystrophy was placed on clinical hold by the FDA but could be upgraded to a pivotal study as a result.
Sarepta taps Invitae to identify participants for DMD trials by Nick Paul Taylor Monday, May 7, 2018 The initiative taps into the networks Invitae has built up to connect sponsors to patients and the clinicians responsible for their care.